Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danirixin dose-ranging study in adults with COPD
2016-003675-21Phase 2Completed
- Sponsor
- GSK
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Danirixin twice daily with Placebo twice daily (2 arms). Primary endpoint: Change from baseline in respiratory symptoms measured by E-RS:COPD daily diary. Started Mar 2017; status: completed.
02
Drugs
danirixin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2016-003675-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003675-21.